AtriCure (ATRC) Projected to Release Quarterly Earnings on Thursday

AtriCure (NASDAQ:ATRC) is expected to be issuing its Q2 2026 results after the market closes on Thursday, July 23rd. Analysts expect AtriCure to post earnings of $0.03 per share and revenue of $151.8040 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 23, 2026 at 4:30 PM ET.

AtriCure Price Performance

NASDAQ:ATRC opened at $34.51 on Wednesday. AtriCure has a 52 week low of $25.36 and a 52 week high of $43.18. The company has a market capitalization of $1.75 billion, a P/E ratio of -345.10 and a beta of 1.24. The stock’s fifty day moving average is $29.67 and its two-hundred day moving average is $31.48. The company has a quick ratio of 3.18, a current ratio of 4.29 and a debt-to-equity ratio of 0.15.

Insider Activity at AtriCure

In related news, Director Karen Prange sold 3,000 shares of AtriCure stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total transaction of $85,950.00. Following the transaction, the director owned 26,373 shares in the company, valued at approximately $755,586.45. The trade was a 10.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On AtriCure

A number of institutional investors have recently added to or reduced their stakes in ATRC. Invesco Ltd. raised its holdings in AtriCure by 7.9% in the fourth quarter. Invesco Ltd. now owns 74,435 shares of the medical device company’s stock valued at $2,945,000 after acquiring an additional 5,462 shares in the last quarter. Mackenzie Financial Corp boosted its holdings in shares of AtriCure by 5.3% in the fourth quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock valued at $545,000 after acquiring an additional 683 shares in the last quarter. XTX Topco Ltd boosted its stake in AtriCure by 88.0% during the fourth quarter. XTX Topco Ltd now owns 11,069 shares of the medical device company’s stock valued at $438,000 after buying an additional 5,182 shares in the last quarter. Susquehanna Portfolio Strategies LLC bought a new stake in AtriCure during the fourth quarter worth approximately $3,415,000. Finally, Engineers Gate Manager LP increased its stake in AtriCure by 104.2% in the 4th quarter. Engineers Gate Manager LP now owns 58,479 shares of the medical device company’s stock worth $2,313,000 after purchasing an additional 29,839 shares in the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Canaccord Genuity Group boosted their price objective on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Freedom Capital raised AtriCure to a “strong-buy” rating in a research report on Wednesday, April 1st. Raymond James Financial set a $52.00 price target on AtriCure in a research note on Tuesday. Wall Street Zen cut AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Weiss Ratings cut AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $49.12.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.